Gene and Cell Therapies Targeting CNS Disorders Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Brainstorm Cell Therapeutics, MeiraGTx, Voyager

Posted on
by

Gene and Cell Therapies Targeting CNS Disorders Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Brainstorm Cell Therapeutics, MeiraGTx, Voyager
The Gene and Cell Therapies Targeting CNS Disorders Market Forecast report offers an in-depth understanding of the Gene and Cell Therapies Targeting CNS Disorders, historical and forecasted epidemiology as well as the Gene and Cell Therapies Targeting CNS Disorders market trends in the 7MM.

DelveInsight’s “Gene and Cell Therapies Targeting CNS Disorders Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gene and Cell Therapies Targeting CNS Disorders, historical and forecasted epidemiology as well as the Gene and Cell Therapies Targeting CNS Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Gene and Cell Therapies Targeting CNS Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gene and Cell Therapies Targeting CNS Disorders Market Forecast

 

Some of the key facts of the Gene and Cell Therapies Targeting CNS Disorders Market Report: 

  • The Gene and Cell Therapies Targeting CNS Disorders market size was valued approximately USD 1 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In December 2023, Brainstorm Cell Therapeutics released the findings of their FDA meeting, stating, “Our discussion with the FDA has offered us valuable guidance regarding the Phase II trial design, delineating clear pathways for progress.
  • In December 2023, uniQure provides an update on the Phase I/II clinical trials of AMT-130 gene therapy for Huntington’s disease treatment. Mean CSF NfL levels show positive trends, with low-dose patients below baseline at 30 months and high-dose patients near baseline at 18 months.
  • As per SMA foundation (2023), Spinal muscular atrophy affect as many as 10,000 to 25,000 children and adults in the United States. One in 6,000 to one in 10,000 children are born with the disease
  • A recent analysis revealed that the prevalence of MS in Europe averages 108 instances per 100,000 people, while in Italy, the prevalence is projected to be 113/100,000, with a ratio of women to males of 1.75:1. This information comes from a study by V. Perrone et al. (2022)
  • ZOLGENSMA is yet another approved treatment. The US FDA authorised ZOLGENSMA in May 2019 for the treatment of paediatric patients with SMA who are younger than 2 years old and have bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. After the Japanese Ministry of Health, Labour, and Welfare (MHLW) approved ZOLGENSMA, Novartis Pharma announced that the European Commission (EC) had granted conditional approval for ZOLGENSMA in May 2020
  • DelveInsight’s analysis indicates that the total diagnosed prevalent population of amyotrophic lateral sclerosis (ALS) in the 7MM was approximately 50,000 in 2021.
  • According to a study by Yohrling. G et al. (2020), there are currently at least 21,331 people who have been diagnosed with Huntington’s disease, but the true frequency of the disease in the US is believed to be 41,467
  • Key Gene and Cell Therapies Targeting CNS Disorders Companies: In8bio Inc., Brainstorm Cell Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Atara Biotherapeutics, Neuroplast, UniQure Biopharma, Asklepios Biopharmaceutical, Inc., Brain Neurotherapy Bio, Inc., Myrtelle Inc., Forge Biologics, Inc, Sio Gene Therapies, Lexeo Therapeutics, Partner Therapeutics, Inc., Hoffmann-La Roche, Novartis, Freeline Therapeutics, Passage Bio, Inc., Black Diamond Therapeutics, Inc., and others
  • Key Gene and Cell Therapies Targeting CNS Disorders Therapies: DRI cell therapy, NurOwn, VY-AADC02, ATA188, Neuro-Cells, AMT-130, AAV2-GDNF, rAAV-Olig001-ASPA, FBX-101, AAV9-GLB1, LX2006, Sargramostim, Entrectinib, ACTUS-101, Capmatinib, FLT201, PBKR03, BDTX-4933, and others
  • The Gene and Cell Therapies Targeting CNS Disorders market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gene and Cell Therapies Targeting CNS Disorders pipeline products will significantly revolutionize the Gene and Cell Therapies Targeting CNS Disorders market dynamics.

 

Gene and Cell Therapies Targeting CNS Disorders Overview

Gene and cell therapies targeting central nervous system (CNS) disorders involve innovative approaches to treat neurological conditions by addressing underlying genetic or cellular abnormalities. These therapies aim to deliver therapeutic genes or cells directly to the brain or spinal cord to correct or replace dysfunctional cells, restore normal function, or slow disease progression.

 

Get a Free sample for the Gene and Cell Therapies Targeting CNS Disorders Market Report 

https://www.delveinsight.com/report-store/gene-and-cell-therapies-targeting-cns-disorders-market

 

Gene and Cell Therapies Targeting CNS Disorders Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Gene and Cell Therapies Targeting CNS Disorders Epidemiology Segmentation:

The Gene and Cell Therapies Targeting CNS Disorders market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Gene and Cell Therapies Targeting CNS Disorders
  • Prevalent Cases of Gene and Cell Therapies Targeting CNS Disorders by severity
  • Gender-specific Prevalence of Gene and Cell Therapies Targeting CNS Disorders
  • Diagnosed Cases of Episodic and Chronic Gene and Cell Therapies Targeting CNS Disorders

 

Download the report to understand which factors are driving Gene and Cell Therapies Targeting CNS Disorders epidemiology trends @ Gene and Cell Therapies Targeting CNS Disorders Epidemiology Forecast

 

Gene and Cell Therapies Targeting CNS Disorders Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gene and Cell Therapies Targeting CNS Disorders market or expected to get launched during the study period. The analysis covers Gene and Cell Therapies Targeting CNS Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gene and Cell Therapies Targeting CNS Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Gene and Cell Therapies Targeting CNS Disorders Therapies and Key Companies

  • DRI cell therapy: In8bio Inc.
  • NurOwn: Brainstorm Cell Therapeutics
  • VY-AADC02: Neurocrine Biosciences/Voyager Therapeutics
  • ATA188: Atara Biotherapeutics
  • Neuro-Cells: Neuroplast
  • AMT-130: UniQure Biopharma
  • AAV2-GDNF: Asklepios Biopharmaceutical, Inc./Brain Neurotherapy Bio, Inc.
  • rAAV-Olig001-ASPA: Myrtelle Inc.
  • FBX-101: Forge Biologics, Inc
  • AAV9-GLB1: Sio Gene Therapies
  • LX2006: Lexeo Therapeutics
  • Sargramostim: Partner Therapeutics, Inc.
  • Entrectinib: Hoffmann-La Roche
  • ACTUS-101: Asklepios Biopharmaceutical, Inc.
  • Capmatinib: Novartis
  • FLT201: Freeline Therapeutics
  • PBKR03: Passage Bio, Inc.
  • BDTX-4933: Black Diamond Therapeutics, Inc.

 

Discover more about therapies set to grab major Gene and Cell Therapies Targeting CNS Disorders market share @ Gene and Cell Therapies Targeting CNS Disorders Treatment Market

 

Gene and Cell Therapies Targeting CNS Disorders Market Strengths

  • Cell and gene therapies (CGT) are the new frontier of medicine, offering life extension and sometimes cures for previously untreatable conditions.

 

Gene and Cell Therapies Targeting CNS Disorders Market Opportunities

  • Larger firms have an edge in the gene therapy industry because they have the resources and expertise to organize intricate development pathways

 

Scope of the Gene and Cell Therapies Targeting CNS Disorders Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Gene and Cell Therapies Targeting CNS Disorders Companies: In8bio Inc., Brainstorm Cell Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Atara Biotherapeutics, Neuroplast, UniQure Biopharma, Asklepios Biopharmaceutical, Inc., Brain Neurotherapy Bio, Inc., Myrtelle Inc., Forge Biologics, Inc, Sio Gene Therapies, Lexeo Therapeutics, Partner Therapeutics, Inc., Hoffmann-La Roche, Novartis, Freeline Therapeutics, Passage Bio, Inc., Black Diamond Therapeutics, Inc., and others
  • Key Gene and Cell Therapies Targeting CNS Disorders Therapies: DRI cell therapy, NurOwn, VY-AADC02, ATA188, Neuro-Cells, AMT-130, AAV2-GDNF, rAAV-Olig001-ASPA, FBX-101, AAV9-GLB1, LX2006, Sargramostim, Entrectinib, ACTUS-101, Capmatinib, FLT201, PBKR03, BDTX-4933, and others
  • Gene and Cell Therapies Targeting CNS Disorders Therapeutic Assessment: Gene and Cell Therapies Targeting CNS Disorders current marketed and Gene and Cell Therapies Targeting CNS Disorders emerging therapies
  • Gene and Cell Therapies Targeting CNS Disorders Market Dynamics: Gene and Cell Therapies Targeting CNS Disorders market drivers and Gene and Cell Therapies Targeting CNS Disorders market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Gene and Cell Therapies Targeting CNS Disorders Unmet Needs, KOL’s views, Analyst’s views, Gene and Cell Therapies Targeting CNS Disorders Market Access and Reimbursement 

 

To know more about Gene and Cell Therapies Targeting CNS Disorders companies working in the treatment market, visit @ Gene and Cell Therapies Targeting CNS Disorders Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Gene and Cell Therapies Targeting CNS Disorders Market Report Introduction

2. Executive Summary for Gene and Cell Therapies Targeting CNS Disorders

3. SWOT analysis of Gene and Cell Therapies Targeting CNS Disorders

4. Gene and Cell Therapies Targeting CNS Disorders Patient Share (%) Overview at a Glance

5. Gene and Cell Therapies Targeting CNS Disorders Market Overview at a Glance

6. Gene and Cell Therapies Targeting CNS Disorders Disease Background and Overview

7. Gene and Cell Therapies Targeting CNS Disorders Epidemiology and Patient Population

8. Country-Specific Patient Population of Gene and Cell Therapies Targeting CNS Disorders 

9. Gene and Cell Therapies Targeting CNS Disorders Current Treatment and Medical Practices

10. Gene and Cell Therapies Targeting CNS Disorders Unmet Needs

11. Gene and Cell Therapies Targeting CNS Disorders Emerging Therapies

12. Gene and Cell Therapies Targeting CNS Disorders Market Outlook

13. Country-Wise Gene and Cell Therapies Targeting CNS Disorders Market Analysis (2019–2032)

14. Gene and Cell Therapies Targeting CNS Disorders Market Access and Reimbursement of Therapies

15. Gene and Cell Therapies Targeting CNS Disorders Market Drivers

16. Gene and Cell Therapies Targeting CNS Disorders Market Barriers

17.  Gene and Cell Therapies Targeting CNS Disorders Appendix

18. Gene and Cell Therapies Targeting CNS Disorders Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/